Epstein-Barr virus (EBV) is a human oncogenic herpesvirus associating with several malignant diseases. Latent
membrane protein 2 (LMP2) of EBV is considered to be an ideal candidate for immunotherapy or prophylactic EBV vaccine.
We designed a LMP2 multiepitope containing T and B-cell epitope-rich peptides and constructed a recombinant
plasmid containing mammalian codonoptimization EBV LMP2 multiepitope (pcDNA3.1(+)/EBV-LMP2 multiepitope).
After pcDNA3.1(+)/EBV-LMP2 multiepitope was transfected into COS-7 cells, significant expression of the multiepitope
in COS-7 cells was confirmed by RT-PCR and immunofluorescence assay. Western blot analysis indicated that serum
from immunized mice could be discerned by the EBV-LMP2 protein and the EBV-LMP2 multiepitope specifically. The
plasmid DNA of EBV-LMP2 multiepitope induced high levels anti-EBV membrane protein and anti-EBV LMP2 multiepitope
IgG in mice. T lymphocytes from spleen of immunized mice showed a strong CTL activity. The present study suggested
that plasmid DNA encoding EBV LMP2 multiepitope capable of stimulating enough cellular and humoral immunity
could have potential for preventing or controlling EBV infection and EBV associated disease in mice.
Keywords: EBV, LMP2, multiepitope, DNA vaccine.
Rights & PermissionsPrintExport